Prevalence of HFE (hemochromatosis gene) mutations in unselected male patients with type 2 diabetes☆,☆☆
Section snippets
Patients
Two-hundred twenty white male patients with type 2 diabetes were recruited from the Bertram Diabetes Centre and from two large local general practice populations after ethical committee approval and written informed consent were obtained. Patients were studied if they were between 21 and 70 years of age at the time of diagnosis, had been taking oral hypoglycemics for at least 6 months, and had a body mass index of less than 32 kg/m2. Insulin treatment was not an exclusion as long as patients
Clinical features
Mean age of the patients with type 2 diabetes was 59.6 years (SD 8.2 years) and did not differ from the age-identical control subjects. Mean known duration of type 2 diabetes was 8.8 years (SD 6.5 years).
845A/845A mutant homozygote
One of the 220 patients (0.4%; 95% confidence interval 0% to 1.3%) and 1 of the 220 control subjects (0.4%; 95% confidence interval 0% to 1.3%) were homozygous for this mutation (P = 1.0).
Compound heterozygote 845G/845A with 187C/187G
Three of the 220 patients (1.4%) and 2 of the 220 control subjects (0.9%) were compound heterozygotes for
Discussion
We did not detect an excess of HFE mutations in patients with type 2 diabetes as compared with matched control subjects without known diabetes. This was despite biasing patient selection toward younger white male patients, a population most likely to clinically express these alleles, inasmuch as 15.9% of male patients with recognized HH have impaired glucose tolerance.13 Previous clinical studies in patients with diabetes have failed to detect an excess of HH as compared with the background
Acknowledgements
We thank Dr Henry Crawley and colleagues (Holt General Practice, Holt, England) and Dr David Pickersgill and colleagues (Birchwood Surgery, North Walsham, England) for their help with this study and for allowing access to their patients.
References (27)
- et al.
hemochromatosis gene mutation in hepatocellular cancer
Lancet
(1997) - et al.
A high prevalence of HLA-H 845A mutations in hemochromatosis patients and the normal population in eastern England
Blood Cell Mol Dis
(1997) Diagnosis of hemochromatosis
Gastroenterology
(1983)- et al.
Arthropathy, hypouricemia and normal serum iron studies in hereditary hemochromatosis
Am J Med
(1981) - et al.
Diagnosis of hemochromatosis in young subjects: predictive accuracy of biochemical screening tests
Gastroenterology
(1984) - et al.
Prevalence of genetic hemochromatosis among diabetic patients [comment]
Lancet
(1989) - et al.
Screening for hemochromatosis: a cost-effectiveness study based on 12,258 patients
Gastroenterology
(1994) - et al.
C282Y mutation in HFE (hemochromatosis) gene and type 2 diabetes
Lancet
(1998) - et al.
Recovery of pancreatic beta-cell function in hemochromatosis: combined treatment with recombinant human erythropoietin and phlebotomy
Am J Med Sci
(1997) - et al.
Letter
Lancet
(1998)
Screening for hemochromatosis
N Engl J Med
Global prevalence of putative hemochromatosis mutations
J Med Genet
Serum iron studies do not identify patients with end stage liver disease
Gastroenterology
Cited by (36)
EASL clinical practice guidelines for HFE hemochromatosis
2010, Journal of HepatologyCitation Excerpt :A higher prevalence of C282Y homozygosity was only found in patients with well-characterized chondrocalcinosis [81]. Association of the C282Y polymorphism with diabetes mellitus has been mainly evaluated in patients with type 2 diabetes mellitus in cross-sectional and case-control studies [84–95]. Apart from one exception, no association between type 2 diabetes and C282Y homozygosity was found [75].
Prevalence of type 2 diabetes mellitus and chronic liver disease: A retrospective study of the association of two increasingly common diseases in Mexico
2010, Annals of HepatologyCitation Excerpt :It is estimated that chronic liver diseases will increase in incidence because of improvements in treatment, which will augment life expectancy, allowing for the development of diabetes in patients with these diseases. Additionally, diabetes mellitus is also predicted to increase in prevalence and incidence around the world, including in Mexico where it is already a significant public health issue as the ninth most frequent cause of morbidity and the first cause of mortality.4,42 As seen in our study population, who were prone to glucose intolerance, IR and related complications, hepatogenous diabetes should be thoroughly investigated with the diagnosis of T2DM or chronic liver disease.
Endocrine consequences of hemochromatosis
2007, Presse MedicaleIron overload and insulin resistance
2005, Presse MedicaleHFE mutations in the elderly
2003, Blood Cells, Molecules, and Diseases
- ☆
Reprint requests: M. J. Sampson, MD, Department of Diabetes and Endocrinology, Norfolk and Norwich Hospital, Brunswick Road, Norwich NR1 3SR UK.
- ☆☆
0022-2143/2000 $12.00 + 0 5/1/104464